20200515 BT-001_AACR curtain raiser EN
Category: Press release
Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050
20200515_AACR myvac curtain raiser EN
Transgene reports Q1 2020 financial position and business update
20200506 TG FINANCIAL T1- US
Vaxxel acquires Transgene’s DuckCelt®-T17 cell line to develop industrial-scale vaccines against respiratory viruses
20200504 – TG Vaxxell EN
Availability of Transgene’s 2019 Universal Registration Document and update on the effect of Covid-19
20200402PR-EN availability URD 2019
Availability of Preparatory Documents for the Combined General Meeting of May 27, 2020
20200403 – availability doc AG – EN
Major R&D milestones achieved in 2019 and strong clinical activity in 2020
20200311 Resultats 2019 EN
Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
20200303 BT-001 presentations EN
First Patient Dosed with Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer with Liver Metastases
20200220 PR FPI 6002.03 EN
Transgene and NEC Start Two Clinical Trials with TG4050, an individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
20200107 PR TG4050 FPI – EN